<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537182</url>
  </required_header>
  <id_info>
    <org_study_id>SINCERE</org_study_id>
    <nct_id>NCT04537182</nct_id>
  </id_info>
  <brief_title>Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema</brief_title>
  <acronym>SINCERE</acronym>
  <official_title>Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema: a Multi-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isabelle Opitz, Professor, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to perform a randomized controlled trial that compares bilateral lung&#xD;
      volume reduction surgery (LVRS) with bronchoscopic lung volume reduction (BLVR) using&#xD;
      endobronchial valves in terms of efficacy and patient safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advanced lung emphysema has a considerable impact on quality of life in patients with chronic&#xD;
      obstructive pulmonary disease. There are positive reports of surgical as well as&#xD;
      bronchoscopic volume reduction in selected patients, but data comparing LVRS and BLVR is&#xD;
      unfortunately lacking to date. The investigators therefore anticipate that their study will&#xD;
      make an important contribution to the worldwide efforts in better understanding selection and&#xD;
      management of surgical and bronchoscopic treatment of emphysema patients and that it will be&#xD;
      of high public interest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, open label, morphology- and site-stratified, 1:1 randomized, actively controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline value in FEV1 (ml)</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Percent change in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in FEV1</measure>
    <time_frame>3 and 12 months after intervention</time_frame>
    <description>Percent change in forced expiratory volume (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in RV</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Percent change in residual volume (RV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in TLC</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Percent change in total lung capacity (TLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in RV/TLC</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Percent change in RV-to-TLC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in DLCO</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Percent change in diffusion capacity (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in 6-minute walking distance</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Distance that can be walked within 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline value in mMRC dyspnea score</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life (SGRQ, EQ-5D-5L)</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>St. George's Respiratory Questionnaire to assess quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline regarding pain (PDI score)</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Pain Disability Index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline regarding pain (VAS)</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Pain assessment with visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of (serious) adverse events / re-interventions</measure>
    <time_frame>3, 6 and 12 months after intervention</time_frame>
    <description>Number and degree of adverse events after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-days mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Number of deaths (all causes) 1 month after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Number of deaths (all causes) 3 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients alive 1 year after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>LVRS treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLVR study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung volume reduction surgery</intervention_name>
    <description>Lung volume reduction by surgery</description>
    <arm_group_label>LVRS treatment group</arm_group_label>
    <other_name>LVRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopic lung volume reduction with valves</intervention_name>
    <description>Lung volume reduction with endobronchial valves.</description>
    <arm_group_label>BLVR study group</arm_group_label>
    <other_name>BLVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from emphysema (all morphologies) potentially qualifying for both&#xD;
             study procedures, LVRS or BLVR (perfusion scintigraphy within &lt; 6 month of screening,&#xD;
             CT scan within &lt; 3 months of screening)&#xD;
&#xD;
          -  • Patients with bilateral emphysema not exceeding perfusion and/or volume side&#xD;
             differences of 70%:30% and therefore allowing a primary bilateral LVRS (borderline&#xD;
             perfusion results regarding side dominance (+/- 5%) are accepted as long as CT&#xD;
             morphology and volume-based perfusion morphology are suitable for bilateral LVRS)&#xD;
&#xD;
          -  Age ≥ 30 and ≤ 80 years&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18, but ≤ 35 kg/m2&#xD;
&#xD;
          -  Non-smoking for 3 months prior to screening interview&#xD;
&#xD;
          -  Patient is able to understand and willing to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Post-bronchodilator FEV1 more than 50% predicted&#xD;
&#xD;
          -  TLC less than 100 % predicted, RV less than 175% predicted, RV/TLC less than 58%&#xD;
             predicted, and DLCO ≤ 20% predicted in homogeneous emphysema and DLCO ≤ 15% in&#xD;
             heterogeneous emphysema, respectively&#xD;
&#xD;
          -  PaO2 ≤ 6.0 kPa (45mm Hg) at ambient air (only applicable for homogeneous morphology!)&#xD;
&#xD;
          -  PaCO2 ≥ 6.6 kPa (50 mmHg) at ambient air (only applicable for homogeneous morphology!)&#xD;
&#xD;
          -  Patients with incomplete interlobar fissures as revealed by quantitative computed&#xD;
             tomography analysis with StratX® (fissure completeness ≤ 80%)&#xD;
&#xD;
          -  Patients with collateral ventilation as evidenced by bronchoscopic Chartis®&#xD;
             measurement&#xD;
&#xD;
          -  6-minute walking distance ≥ 450m&#xD;
&#xD;
          -  More than two COPD exacerbation episodes requiring hospitalization in the last year&#xD;
&#xD;
          -  More than two instances of pneumonia episodes in the last year&#xD;
&#xD;
          -  Unplanned weight loss ≥ 10% within 90 days prior to enrollment&#xD;
&#xD;
          -  Pulmonary hypertension as evidenced by Delta Psyst RV-RA &gt; 35 mmHg on recent&#xD;
             echocardiography (within 3 months prior to screening) and confirmed by RHC (mPAP ≥ 35&#xD;
             mmHg) and signs of moderate to severe RV dysfunction.&#xD;
&#xD;
          -  Evidence of left ventricular ejection fraction (LVEF) less than 45% on recent&#xD;
             echocardiography (within 3 months prior to screening)&#xD;
&#xD;
          -  History of exercise-related syncope&#xD;
&#xD;
          -  Myocardial infarction or congestive heart failure within 6 months of screening&#xD;
&#xD;
          -  Clinically significant arrhythmias that might put the patient at risk in regard to the&#xD;
             interventions&#xD;
&#xD;
          -  Prior LVR (any method), bullectomy, or lobectomy&#xD;
&#xD;
          -  Clinically significant bronchiectasis with expectoration of ≥ 2 tablespoons/day.&#xD;
&#xD;
          -  Pulmonary nodule requiring surgery&#xD;
&#xD;
          -  Unable to safely discontinue anticoagulants or dual antiplatelet therapy for 7 days&#xD;
&#xD;
          -  Patients with a life expectancy of less than one year&#xD;
&#xD;
          -  Any disease or condition that interferes with completion of initial or follow-up&#xD;
             assessment&#xD;
&#xD;
          -  Currently listed for lung transplantation&#xD;
&#xD;
          -  Daily dose of prednisone ≥ 10mg&#xD;
&#xD;
          -  Current enrollment in another clinical trial studying an experimental treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Opitz, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Opitz, Prof. MD</last_name>
    <phone>+41 44 255 11 11</phone>
    <email>isabelle.schmitt-opitz@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadine Bosbach, MSc</last_name>
    <phone>+41 44 255 92 30</phone>
    <email>nadine.bosbach@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Gambazzi, MD</last_name>
      <email>franco.gambazzi@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daiana Stolz, Prof MD</last_name>
      <email>daiana.stolz@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Thoracic Surgery</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Opitz, Prof MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>isabelle.schmitt-opitz@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Isabelle Opitz, Professor, MD</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <keyword>LVRS</keyword>
  <keyword>BLVR</keyword>
  <keyword>endobronchial valves</keyword>
  <keyword>heterogeneous empyhsema</keyword>
  <keyword>non-heterogeneous emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

